
Protara Therapeutics, Inc.: updates and filings
Price
$2.28
November 20, 2026Market cap $140M
What Ploutos Investor adds for Protara Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 6, 2026next Feb 5, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 6, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 6, 2026Results of operationsForm8-K
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Shares registered for employeesFormS-8
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operationsForm8-K
- Jul 7, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 29, 2026Officer or director changeForm8-K
- Jun 15, 2026Shareholder voteForm8-K
- May 22, 2026FilingFormEFFECT
- May 20, 2026Correspondence with the SECFormCORRESP
- May 19, 2026Letter from the SECFormUPLOAD
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Shelf registration for future offeringsFormS-3
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Apr 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 17, 2026Preliminary proxy statementFormPRE 14A
- Mar 30, 2026Regulation FD disclosureForm8-K
- Mar 10, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 10, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 6, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 6, 2026 | 8-K | Results of operations | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | S-8 | Shares registered for employees | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Jul 7, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 29, 2026 | 8-K | Officer or director change | Document |
| Jun 15, 2026 | 8-K | Shareholder vote | Document |
| May 22, 2026 | EFFECT | Filing | Document |
| May 20, 2026 | CORRESP | Correspondence with the SEC | Document |
| May 19, 2026 | UPLOAD | Letter from the SEC | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | S-3 | Shelf registration for future offerings | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 17, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Mar 30, 2026 | 8-K | Regulation FD disclosure | Document |
| Mar 10, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 10, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 14, 2006.
The full analysis
What do Protara Therapeutics's filings show?
The filings are where every one of Protara Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.